companies / targedbio-com
Generated UTC · publication cutoff 2026-11-09
Insufficient cited evidence for a two-sentence summary.
verified=2026-05-08 json
| total_raised | 5,121,4005.1M | ○ |
|---|---|---|
| founded | null | |
| hq | Biopharmaceuticals | |
| industry | unknown | |
| stage | null |
TargED develops targeted thrombolytic drugs that use small VHH antibodies to deliver clot-dissolving enzymes directly to a thrombus. It targets patients with thrombotic disorders such as acute ischemic stroke and iTTP. Its differentiator is localized enzyme delivery that works regardless of clot composition.
No cited completed company acquisition recorded.
Dated disclosures. Customer relationships and classifications are historical; ARR is separate from revenue.
No cited disclosure recorded: named customer, disclosed revenue, ARR, count, B2B / B2C, sector, go-to-market.
No cited valuation with an explicit basis is recorded.
Historical post-money / actual annual or stated TTM revenue. Same currency; economic valuation date within 90 days of revenue period end, inclusive. No FX, ARR, annualized revenue, estimates or projections. Conflicts and ambiguous ties are withheld.
No qualifying pair recorded.
| date | type | amount | lead | src |
|---|---|---|---|---|
| 2025-06-30 | grant | 2,700,0002.7M | null | ○ |
WordPress, Yoast SEO 27.6, Underscore.js 1.13.8, Font Awesome, jQuery Migrate 3.4.1, jsDelivr, Varnish, OpenResty, Nginx, PHP, MySQL, jquery 3.7.1
| fact | status | src |
|---|---|---|
| Grant, $2.7M | attributed | ○ |
| existence | self-reported | WEB |
| description | self-reported | WEB |